Medical Director, Oncology

Article

We are recruiting board-certified oncologists for full and part time positions. Responsibilities include leading teams of health professionals, peer-to-peer discussions with physicians, collaborating with clinical content specialists; and opportunity for health services research. This position is for the individual seeking a change in career direction that is both dynamic and challenging.

We are recruiting board-certified oncologists for full and part time positions. Responsibilities include leading teams of health professionals, peer-to-peer discussions with physicians, collaborating with clinical content specialists; and opportunity for health services research. This position is for the individual seeking a change in career direction that is both dynamic and challenging.

 

eviti, Inc. is a leading health IT company implementing solutions to ensure that patients receive high quality care including access to clinical trials.

 

Over 2,000 oncology practices use eviti Connect for automated certification, and eviti Advisor for oncology decision support.

 

Medical Directors report to Arlene Forastiere, M.D.

 

Interested candidates should contact:
Maureen Horstmann, Director of Human Resources
maureen.horstmann@eviti.com, 215-569-0656, ext. 140

 

www.eviti.com

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
2 experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Related Content